OncoSec Medical Incorporated

820 Bear Tavern Road

Ewing, New Jersey 08628

February 28, 2023

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:  

OncoSec Medical Incorporated

Request for Withdrawal of Registration Statement on Form S-1

Filed on February 1, 2023

File No. 333-269517

 

Ladies and Gentlemen:

 

Pursuant to Rule 477 of the Securities Act of 1933, as amended (“Securities Act”), OncoSec Medical Incorporated, a Nevada corporation (the “Company”), hereby respectfully requests that that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Registration Statement on Form S-1 (File No. 333-269517), together with all exhibits and amendments thereto, as initially filed with the Commission on February 1, 2023 (collectively, “Registration Statement”), effective immediately or at the earliest practicable date hereafter.

 

The Company is seeking withdrawal of the Registration Statement because it opted not to pursue the offering contemplated thereby at this time. The Company confirms that the Registration Statement has not been declared effective and that no securities have been sold pursuant to the Registration Statement.

 

Accordingly, the Company requests that the Commission issue an order granting the withdrawal of the Registration Statement (the “Order”) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to the undersigned at 820 Bear Tavern Road, Ewing, New Jersey 08628, with a copy to Christopher L. Tinen of Procopio, Cory, Hargreaves & Savitch LLP via email at Christopher.Tinen@procopio.com or via facsimile at (619) 744-5459.

 

Additionally, in accordance with Rule 457(p) of the Securities Act, the Company requests that all fees paid to the Commission in connection with the initial filing of the Registration Statement be credited for future use by the Company.

 

Should you have any questions regarding this request for withdrawal, or if you require any additional information, please contact Christopher L. Tinen of Procopio, Cory, Hargreaves & Savitch LLP by telephone at (858) 720-6320.

 

  Very truly yours,
     
    /s/ Robert H. Arch
  Name: Robert H. Arch
  Title: President and Chief Executive Officer

 

 

 

 

OncoSec Medical (NASDAQ:ONCS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 OncoSec Medical 차트를 더 보려면 여기를 클릭.
OncoSec Medical (NASDAQ:ONCS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 OncoSec Medical 차트를 더 보려면 여기를 클릭.